R & D

Advancing Long Life with Innovation of Science and Technology

Pipeline
Manufacturing
Collaborations & Partnership

Pipeline

Allist will strive to take its advantages in new drug discovery, increase R&D inputs, and intensify its efforts in accelerating exploring targeted drugs for cancer treatment.Meanwhile, Allist is working to expand its product pipeline in multiple ways including joint development and external introduction.

Furmonertinib
(Core product)

Approved

Second-line therapy for Non-small Cell Lung Cancer (NSCLC):EGFR T790M mutation-positive, locally advanced or metastatic NSCLC

APPROVED

First-line therapy for Non-small Cell Lung Cancer (NSCLC):EGFR mutation-positive, locally advanced or metastatic NSCLC

Phase III enrollment

Postoperative adjuvant therapy of NSCLC:Postoperative adjuvant therapy for patients with EGFR mutation-positive NSCLC at phase 1I-IIIa

Phase Ib enrollment

Second-line therapy for NSCLC:Applicable to advanced NSCLC with EGFR ex20ins mutation

Phase Ib enrollment

First-line therapy for NSCLC:Applicable to advanced NSCLC with EGFR ex20ins mutation

RETinhibitor

Preclinical study

NSCLC

KRAS G12C
inhibitor

Preclinical study

NSCLC, colorectal cancer, pancreatic cancer

KRAS G12D
inhibitor

Preclinical study

NSCLC, colorectal cancer, pancreatic cancer

SOS1
inhibitor

Preclinical study

NSCLC, colorectal cancer, pancreatic cancer

4^th-generationEGFR
inhibitor

Preclinical study

NSCLC with C797S drug-resistant mutation after treatment with 3rd-generation EGFR inhibitor

Treatment of Malignant Tumor

Manufacturing

73,337

Square meter
240

Million RMB
(registered capital)

As an innovative pharmaceutical industrialization base invested by Shanghai Allist Pharmaceuticals, Jiangsu Allist Pharmaceuticals Co.,LTD was founded in Sept 2009 with a registered capital of 240 million RMB.Jiangsu Allist is located in No.666 Huashi Road, Qidong Economic Development Zone, Jiangsu Province, covering a total area of 73,337 square meter, 90Km away from Shanghai Pudong Airport, with convenient transportation and beautiful environment.

Scope of production license: Tablets (including antitumor drugs) and hard capsules (including antitumor drugs)

Collaborations & Partnership

Focused on Cancer and other Maior Therapeutical Areas with Unmet Clinical Demands
ALLISTBD@cyuav.com
Cooperation Advantages
Collaborative Partners

Cooperation Advantages

R&D Capability

Two innovative drugs have been successfully developed and put into market, leading in China
Core technology platforms: Drug molecular design and discovery technology, drug design and optimization technology based on metabolism, with high success rate, good practicability and R&D efficiency;
Clinical Resources

Rich resources of clinical experts, especially in Lund Cancer;
Superior ability of translational medicine, highly recognized by clinical experts and peers of international top journals;
Professional and efficient clinical operation team and management;
RA Advantage

With closed-loop development experience in the process of innovative drug development "R&D-Preclinical evalsuation-Clinical Transformation-Registration-Commercial Operation"
Sales Network

Wide and deep commercial operation network;
More than 350 talents for sales with extensive resources and rich experience;

尊龙凯时